Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences: Sales of Sapien transcatheter aortic heart valves in Europe reach $2 million in the fourth quarter of 2007 and will increase to $20 million in 2008, CEO Michael Mussallem reports Feb. 5. The device gained a CE mark clearance last September and is in clinical trials in the U.S. (1"The Gray Sheet" Feb. 4, 2008, In Brief). Edwards' overall heart valve sales of $131.4 million for the quarter were up 9% from a year ago, led by a "strong" international performance. Critical care segment sales grew 20% to $113 million, led by the FloTrac cardiac output monitoring system. Corporate sales of $293 million were up 10.3% from the fourth quarter of 2006